

Hong Kong Exchange
Limited take no responsibility
representation as to its
whatsoever for any loss
part of the contents of the

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

ANNOUNCEMENT

PROPOSED ISSUANCE OF CORPORATE BONDS AND CHANGE IN USE OF PROCEEDS

PROPOSED ISSUANCE OF CORPORATE BONDS

On 30 June 2022, the Board of Directors of the Company (the "Board") (the "Company") (the "Proposed Issuance") (the "Corporate Bonds") (the "PRC") (the "EGM")

1. ISSUE SIZE

The Company has issued B1,000,000,000 (one billion RMB) (the "B1,000,000,000")

2. TARGET SUBSCRIBERS

B.

3. TERM

B.
().

4. USE OF PROCEEDS

(Proceeds-)
B.

5. INTEREST RATE

B. B.
.

6. VALIDITY OF THE RESOLUTION(S)

() 24
B.
()

Reasons and benefits of the Proposed Issuance

B.
B.

PROPOSED CHANGE IN USE OF PROCEEDS

Use of Proceeds

Document	Year	Amount (B)
Prospectus	2020	B3,538.4
(Net Proceeds)	2020 (Global Offering)	B3,538.4
2022 Interim Report	2022	B3,538.4

Document	Year	Amount (B)	Percentage
A	2020	B1,061.5	30%
	2020	B1,061.5	30%
	2020	B707.7	20%
	2020	B707.7	20%

Document	Year	Amount (B)
A	2022	B1,115.2
	2022	B2,423.2

Proposed Change in Use of Proceeds

B. (Proposed Change in Use of Proceeds)

Business objectives	Original planned use of the Net Proceeds as disclosed in the Prospects (RMB million)	Utilised as at the date of this announcement (RMB million)	Remaining proceeds as at the date of this announcement (RMB million)	Revised allocation of unutilised Net Proceeds (RMB million)	Expected date of full utilisation of the unutilised Net Proceeds
(1) 收购及开发位于中国内地及香港的物业项目	1,061.5 (30% of the net proceeds)	1,034.4	27.1		
(2) 收购及开发位于中国内地及香港的物业项目	1,061.5 (30% of the net proceeds)		1,061.5	636.9	24 months
(3) 收购及开发位于中国内地及香港的物业项目	707.7 (20% of the net proceeds)		707.7	451.8	24 months
(4) 收购及开发位于中国内地及香港的物业项目	707.7 (20% of the net proceeds)	80.8	626.9	376.2	24 months
(5) 收购及开发位于中国内地及香港的物业项目				958.3	24 months
	<u>3,538.4</u>	<u>1,115.2</u>	<u>2,423.2</u>	<u>2,423.2</u>	





Reasons for and benefits of the Proposed Change in Use of Proceeds






2022 -19

B

A

0. B 2.9 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

B.  B.  24 A.  B376.2 

2021  2022  -19,  2022  31 

A

A

B

B B
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

30 2022

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.

** for identification purposes only*